scholarly journals Comparison of the Valuation of Treatment Alternatives in Parkinson's Disease with Best-Worst Scaling, Time Trade-off and Visual Analogue Scales

2014 ◽  
Vol 17 (7) ◽  
pp. A401
Author(s):  
M.G.M. Weernink ◽  
C.G.M. Groothuis-Oudshoorn ◽  
M.J. IJzerman ◽  
J.A. van Til
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Trade Off ◽  
Visual Analogue Scales ◽  
Best Worst Scaling ◽  
Treatment Alternatives ◽  
Analogue Scales

scholarly journals Valuing Treatments for Parkinson Disease Incorporating Process Utility: Performance of Best-Worst Scaling, Time Trade-Off, and Visual Analogue Scales

2016 ◽  
Vol 19 (2) ◽  
pp. 226-232 ◽  
Author(s):  
Marieke G.M. Weernink ◽  
Catharina G.M. Groothuis-Oudshoorn ◽  
Maarten J. IJzerman ◽  
Janine A. van Til
Keyword(s):  
Parkinson Disease ◽  
Trade Off ◽  
Visual Analogue Scales ◽  
Process Utility ◽  
Best Worst Scaling ◽  
Analogue Scales

scholarly journals Movement Speed-Accuracy Trade-Off in Parkinson's Disease

2018 ◽  
Vol 9 ◽  
Author(s):  
Laure Fernandez ◽  
Raoul Huys ◽  
Johann Issartel ◽  
Jean-Philippe Azulay ◽  
Alexandre Eusebio
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Movement Speed ◽  
Trade Off ◽  
Speed Accuracy

Sensorimotor subthalamic stimulation restores risk‐reward trade‐off in Parkinson's disease

2018 ◽  
Vol 34 (3) ◽  
pp. 366-376 ◽  
Author(s):  
Friederike Irmen ◽  
Andreas Horn ◽  
David Meder ◽  
Wolf‐Julian Neumann ◽  
Philip Plettig ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Trade Off ◽  
Subthalamic Stimulation

scholarly journals Treatment of Parkinson’s disease with agents other than Levodopa and Dopamine Agonists: controversies and new approaches

1984 ◽  
Vol 11 (S1) ◽  
pp. 210-220 ◽  
Author(s):  
Anthony E. Lang
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Agonists ◽  
New Approaches ◽  
Wide Range ◽  
The Many ◽  
Treatment Alternatives

ABSTRACTParkinson’s disease is associated with a variety of neurotransmitter disturbances which may be further altered by its treatment with dopamine agonists. Based on this information a wide range of pharmacological approaches have been used in search of newer treatment alternatives and in hopes of reducing complications of long-term levodopa use. This paper reviews the various therapies which have had some success in the management of Parkinson’s disease, other than levodopa and dopamine agonists. Special emphasis is placed on the many unresolved questions and controversies that exist in this area of neuropharmacology.

scholarly journals Handwriting training in Parkinson’s disease: A trade-off between size, speed and fluency

PLoS ONE ◽  
2017 ◽  
Vol 12 (12) ◽  
pp. e0190223 ◽  
Author(s):  
Evelien Nackaerts ◽  
Sanne Broeder ◽  
Marcelo P. Pereira ◽  
Stephan P. Swinnen ◽  
Wim Vandenberghe ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Trade Off

Dyskinesia - Advances in the Understanding of Pathophysiology and Possible Treatment Options

2010 ◽  
Vol 5 (2) ◽  
pp. 34 ◽  
Author(s):  
Hanna S Lindgren ◽  
M Angela Cenci ◽  
Emma L Lane ◽  
◽  
◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopaminergic Neurons ◽  
Treatment Options ◽  
Primary Role ◽  
Therapeutic Approaches ◽  
Abnormal Involuntary Movements ◽  
Treatment Alternatives ◽  
Novel Therapeutic

The degeneration of nigrostriatal dopaminergic neurons in Parkinson’s disease gives rise to tremor and slowness of movement, cardinal motor symptoms of the disease that can be alleviated by the dopamine precursor L-DOPA. Despite this, long-term L-DOPA treatment is hampered by the development of abnormal involuntary movements, i.e. dyskinesia, in the majority of patients. The pathophysiology of dyskinesia is complex and multifactorial, but excessive swings in extracellular dopamine causing aberrant plasticity in dopaminoceptive neurons are attributed a primary role. To date there are few effective treatment alternatives for patients with Parkinson’s disease experiencing dyskinesia, representing an unmet therapeutic need in the treatment strategy of the disease. This article reviews recent findings from both clinical and pre-clinical studies and their impact on the search for novel therapeutic approaches to levodopa-induced dyskinesia.

Sign in / Sign up

Export Citation Format

Share Document